Tempus AI Inc. (NASDAQ:TEM) is one of the 10 worst artificial intelligence stocks under $30 according to short sellers.
During the first week of June, Tempus AI Inc. (NASDAQ:TEM) shared the impending clinical availability for its advanced sequencing test, xH. It detects oncologic targets within bone marrow and peripheral blood samples, based on whole-genome sequencing methodology. The company initially revealed the test for research purposes back in January 2025.
Romaset/Shutterstock.com
The xH test is utilized across various conditions such as myeloproliferative neoplasms (MPN), acute myeloid leukemia (AML), overlap syndromes (MDS/MPN), and myelodysplastic syndromes (MDS). It is also useful for various other functions, including therapeutic research, disease understanding, and biomarker discovery.
The test achieved analytical validation based on an evaluation of 235 specimens, which included cell lines, bone marrow, and whole blood. The validation exhibited a high level of statistical accuracy. It showed PPA of 92.86% for SVs, 93.43% for CNAs, and 97.29% for SNVs and Indels, against their respective benchmarks.
Chief Executive Officer Tom Schonherr highlighted how the company has realized its initial vision of developing xH to introduce a uniform whole-genome sequencing platform with the potential to transform hematologic oncology care. He stated:
“We’ve realized that vision by replacing multiple time-consuming diagnostic tests with a single, high-throughput whole-genome workflow that helps clinicians make faster, smarter decisions. At the same time, xH provides biopharma partners with a comprehensive multiomic foundation to improve clinical trial design, accelerate biomarker discovery, and support the development of next-generation targeted therapies.”
Tempus AI Inc. (NASDAQ:TEM) is a healthcare technology company that offers software tools such as the Tempus platform, Next, Algos, Lens, and Hub. The company offers diagnostic services, including solid tumor and hematologic testing through multiple assays. It also offers genetic tests focused on inherited conditions and clinical trial matching services.
While we acknowledge the risk and potential of TEM as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than TEM and that has 10,000% upside potential, check out our report about this cheapest AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.
Disclosure: None. Follow Insider Monkey on Google News.
